Abstract
Doxorubicin (DOX) is an active and broad spectrum chemotherapeutic agent. Increased inducible nitric oxide synthase (NOS) expression and/or activity have been reported in several human tumors. While the relationship between DOX treatment and the enzymatic activity of endothelial NOS has been well characterized, little is known about the effects of DOX on the expression of iNOS in human cancer cells. In the present study, we characterized the effects of DOX on the nitric oxide (NO) production by colorectal cancer cells, DLD-1. IFN-γ/IL-lβ (CM) increased the production of NO, whereas pretreatment of DOX inhibited the production of NO in response to CM in a dose dependent manner. The increased expressions of iNOS mRNA and protein by CM were completely blocked by DOX without affecting the iNOS mRNA stability. However, DOX activated nuclear factor-KB (NF-κB) in response to CM. Furthermore, the expression of inhibitor κBα was reduced by DOX in a dose dependent manner. Collectively, DOX inhibited the production of NO by DLD-1 cells, which is not linked to well known transcription factor, NF-κB. Therefore, further studies on the possible mechanisms of inhibitory effects of NO production by DOX would be worth pursuing.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ambs, S., Hussain, S.P. and Harris, C.C., Interactive effects of nitric oxide and the p53 tumor suppressor gene in carcinogenesis and tumor progression.FASEB J., 11, 443–448 1997.
Ambs, S., Merriam, W.G., Bennett, W.R, Felley-Bosco, E., Ogunfusika, M.O., Oser, S.M., Klein, S., Shields, P.G., Billiar, T.R. and Harris, C.C., Frequent nitric oxide synthase-2 expression in human colorectal adenomas: Implication for tumor angiogenesis and colorectal cancer progression.Cancer Res., 58, 334–341 1998.
Bian, X., McAllister-Lucas, L.M., Shao, F., Schumacher, K.R., Feng, Z., Porter, A.G., Castle, V.P. and Opipari, A.W.J., NF-kappa B activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells.J. Biol. Chem., 276, 48921–48929 2001.
Brune, B., von Knethen, A. and Sandau, K.B., Nitric oxide and its role in apoptosis.Eur. J. Pharmacol., 351, 261–272 1998.
Chu, S.C., Marks-Konczalik, J., Wu, H., Banks, T.C. and Moss, J., Analysis of the cytokine-stimulated human inducible nitric oxide synthase (iNOS) gene: characterization of differences between human and mouse iNOS promoters.Biochem. Biophys. Res. Commun., 248, 871–878 1998.
Cobbs, C.S., Brenman, J.E., Aldape, K.D., Bredt, D.S. and Israel, M.A., Expression of nitric oxide synthase activity in human central nervous system tumors.Cancer Res., 55, 727–730 1995.
Das, K.C. and White, C.W., Activation of NF-kB by antineoplastic agents.J. Biol. Chem., 272, 14914–14920 1997.
Denizot, F. and Lang, R., Rapid colorimetric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability.J. Immunol. Methods, 89, 271–277 1986.
Dupraz, P., Cottet, S., Hamburger, F., Dolci, W., Felley-Bosco, E. and Thorens, B., Dominant negative MyD88 proteins inhibit interleukin-1 βinterferon-γ-mediated induction of nuclear factor κB-dependent nitrite production and apoptosis in b cells.J. Biol. Chem., 275, 37672–37678 2000.
Foo, S. and Nolan, G., NF-kB to the rescue.Trends Genet., 15, 229–235 1999.
Fukumura, D. and Jain, R.K., Role of nitric oxide in angiogenesis and microcirculation in tumors.Cancer Metastasis Rev., 17, 77–89 1998.
Green, L., Wagner, D.A., Glogowski, J., Skipper, P. I., Wishnok, J.S. and Tannenbaum, S.R., Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids.Anal. Biochem., 126, 131–138 1982.
Heitmeier, M.R., Scarim, A.L and Corbett, J.A., lnterferon-γ increases the sensitivity of islets of langerhans for inducible nitric oxide synthase expression induced by interleukin 1.J. Biol. Chem., 272, 13697–13704 (1997).
Ignao, L., Endothelium-derived nitric oxide: actions and properties.FASEB J., 3, 31–36 (1989).
Inagaki, R., Taniguchi, T., Sakai, T., Hayashi, N., Ishii, Y. and Muramatsu, I., Anticancer drugs inhibit induction of NO synthase in ra.in vivo. Gen. Pharmacol., 32, 185–188 1999.
Jaiswal, M., LaRusso, N.F., Burgart, L.J. and Gores, G.J., Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxidedependent mechanism.Cancer Res., 60, 184–190 2000.
Jenkins, D.C., Charles, I.G., Thomsen, I.T., Moss, D.W., Homes, I.S., Baylis, S.A., Rhodes, P., Westmore, K., Emson, PA. and Moncada, S., Role of nitric oxide in tumor growth.Proc. Natl. Acad. Sci. U.S.A., 92, 4392–4396 1995.
Kalivendi, S.V., Kotamraju, S., Zhao, H., Joseph, J. and Kalyanaraman, B., Doxorubicin-induced apoptosis associated with increased transcription of endothelial nitric-oxide synthase.Cancer Res., 276, 47266–47276 2001.
Lee, H.Y., Lee, J., Kim, E.J., Han, J.W., Lee, H.W., Kang, Y.J. and Chang, K.C, Inhibition of lipopolysaccharide-induced inducible nitric oxide (iNOS) mRNA expression and nitric oxide production by higenamine in murine peritoneal macrophages.Arch. Pharm. Res., 22, 55–59 (1999).
O’Neill, L.A.J., Towards an understanding of the signal transduction pathways for interleukin 1.Biochim Biophys Acta, 1266, 31–44 1995.
Sherman, PA., Laubach, V.E., Reep, B.R. and Wood, E.R., Purification and cDNA sequence of an inducible nitric oxide synthase from a human tumor cell line.Biochemistry, 32, 11600–11605 1993.
Siegert, A., Rosenberg, C., Schmitt, W.D., Denkert, C. and Hauptmann, S., Nitric oxide of human colorectal adenocarcinoma cell lines promotes tumor cell invasion.Br. J. Cancer, 86, 1310–1315 (2002).
Singal, PK. and lliskovic, N., Doxorubicin-induced cardiomyopathy.N. Engl. J. Med., 339, 900–905 1998.
St-Denis, A., Chano, F., Tremblay, P., St-Pierre, Y. and Descoteaux, A., Protein kinase C-a modulates lipopolysaccharide induced functions in a murine macrophage cell line.J. Biol. Chem., 273, 32787–32792 1998.
Thanos, D. and Maniatis, T., NF-kB: a lesson in family values.Cell, 80, 529–532 1995.
Thomsen, L.L., Lawton, F.G., Knowles, R. G., Beesley, J.E., Riveras-Moreno, V. and Moncada, S., Nitric oxide synthase activity in human gynecological cancer.Cancer Res., 54, 1352–1354 1994.
Thomsen, L.L., Miles, D.W., Happerfield, L., Bobrow, L.G., Knowles, R.G. and Moncada, S., Nitric oxide syntase activity in human breast cancer.Br. J. Cancer, 72, 41–44 1995.
Xie, K. and Fidler, I.J., Therapy of cancer metastasis by activation of the inducible nitric oxide synthase.Cancer Metastasis Rev., 17, 55–75 (1998).
Zagozdzon, R., Giermasz, A., Golab, J., Stoklosa, T., Jalili, A. and Jakobisiak, M., The potentiated antileukemic effects of doxorubicin and interleukin-12 combination are not dependent on nitric oxide production.Cancer Lett., 147, 67–75 1999.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jung, I.D., Lee, JS., Yun, S.Y. et al. Doxorubicin inhibits the production of nitric oxide by colorectal cancer cells. Arch Pharm Res 25, 691–696 (2002). https://doi.org/10.1007/BF02976946
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02976946